Drug Combination Details
| General Information of the Combination (ID: C22534) | |||||
|---|---|---|---|---|---|
| Name | Piperlongumine NP Info | + | Oxaliplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Activity | CASP3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| LoVo | CVCL_0399 | Colon adenocarcinoma | Homo sapiens | |||
| GES-1 | CVCL_EQ22 | Healthy | Homo sapiens | |||
| In-vivo Model | For a xenograft model, HCT-116 cells (1*107 in 150 uL PBS) were subcutaneously injected into the right flank of five-week-old female athymic BALB/c nu/nu mice. | |||||
| Experimental
Result(s) |
The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress. Cell Death Dis. 2019 Aug 8;10(8):600. | |||
